Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 22, Issue 3, 2008, Pages 213-217

  Haroutiunian, Simon ^a,b   Rosen, Gila ^a   Shouval, Rivka ^a   Davidson, Elyad ^a,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chronic nonmalignant pain; CNMP; Fibromyalgia; Tetrahydrocannabinol; THC

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; TETRAHYDROCANNABINOL; ANALGESIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANALGESIA; APPETITE; ARTHRALGIA; ARTICLE; BONE PAIN; CHRONIC PAIN; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; DAILY LIFE ACTIVITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; LOW BACK PAIN; MALE; MIGRAINE; MOOD; NAUSEA; NERVOUSNESS; NEUROPATHIC PAIN; OPEN STUDY; PAIN ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SIDE EFFECT; SLEEP; SOCIAL INTERACTION; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; WEIGHT GAIN; CHRONIC DISEASE; CLINICAL TRIAL; INTRACTABLE PAIN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PILOT STUDY; PSYCHOMETRY;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, NON-NARCOTIC; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN, INTRACTABLE; PILOT PROJECTS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; TETRAHYDROCANNABINOL;

EID: 60249088210     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1080/15360280802251215     Document Type: Article

References (9)

1. E R. History of cannabis as a medicine. In Guy GW WBaRP, ed. The Medicinal Use of Cannabis and Cannabinoids. Chicago: Pharmaceutical Press; 2004.
2. Mechoulam R, Gaoni Y. A total synthesis of DlDelta-1- tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc.1965;87:3273-3275.
3. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161-202.
4. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17-24.
5. Zajicek JP, Sanders HP, Wright DEet al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664-1669.
6. Rogers WH, Wittink HM, Ashburn MA, Cynn D, Carr DB. Using the "TOPS,"anoutcomes instrument for multidisciplinary outpatient pain treatment. Pain Med. 2000;1(1):55-67.
7. Ho MJ, LaFleur J. The treatment outcomes of pain survey (TOPS): a clinical monitoring and outcomes instrument for chronic pain practice and research. J Pain Palliat Care Pharmacother. 2004;18(2):49-59.
8. Gershkovich P, Qadri B, Yacovan A, Amselem S, Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur J Pharm Sci. 2007;31(5):298-305.
9. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin. 2006;22(7):1269-1276.